About

Founded in 2010, CG Oncology is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies.

We employ a capital-efficient operating model to achieve expedited product approval. Our strategy is centered on providing patients with new and impactful therapies. Our lead proprietary agent, CG0070, has the potential to deliver safe and effective cancer care alone and in combination with other immunotherapies. CG0070 has been shown to be a safe agent in BCG-failure non-muscle invasive bladder cancer (NMIBC) and we are exploring further types of cancer in clinical studies. At CG Oncology, we aim to take the next evolutionary step in delivering innovative cancer care to millions of patients in need worldwide.

In 2010, CG Oncology acquired the global rights to CG0070 from BioSante Pharmaceuticals. CG Oncology is currently investigating the company’s first product, CG0070, for the treatment of non-muscle invasive bladder cancer in the BCG-unresponsive patient population. In addition, CG Oncology is exploring the use of CG0070 in combination with immune checkpoint inhibitors in various solid tumors.

Management

Arthur Kuan

Chief Executive Officer

Arthur currently serves as Chief Executive Officer and Director on the Board at CG Oncology, a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies, including an oncolytic virus for the treatment of bladder cancer and a variety of other solid tumor types. Arthur is a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, and plays an active role in managing the fund’s portfolio companies. Previously, Arthur was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. He began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Arthur received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.​

James Burke, M.D.

Chief Medical Officer

James currently serves as Chief Medical Officer and is responsible for clinical development at CG Oncology. James was previously CMO at Turnstone Biologics and Jennerex Biotherapeutics / SillaJen. As CMO, he oversaw oversaw global clinical development for oncolytic virus therapies from first-in-human Phase 1 to global Phase 3 studies across diverse solid tumor indications and gene therapy programs. James has over 15 years of preclinical and clinical experience in the field of gene and immunotherapy including work with various oncolytic virus platforms, tumor vaccines, and other gene therapy related agents. Prior to Jennerex, he was Associate Director of Clinical Research at Cell Genesys and was Director of Clinical Research at a regional cancer center. James earned a BS in Biochemistry from University of California, San Diego and an MD from Georgetown University. He completed a general internal medicine residency at University of California, San Diego followed by a Hematology-Oncology Fellowship at University of California, San Francisco.​

Ursula Fritsch, Pharm.D.

Chief Regulatory Officer

Ursula oversees global regulatory affairs, quality and compliance for CG Oncology. During her career, she has overseen the regulatory development of assets from the nonclinical stage through development and post marketing. She has overseen numerous NDA, BLA, IND and special designation submissions. Experienced in both large and small molecules development, Ursula served as the Senior Vice President of Regulatory Affairs and Quality Assurance at SillaJen Biotherapeutics, a global oncolytic company where she was responsible for managing worldwide regulatory and quality compliance of global oncolytic trials. Prior to her position at SillaJen, Ursula served as Vice President of Regulatory Affairs and Quality Assurance at Jennerex. She led the regulatory function at Onyx Pharmaceuticals, Anthera Pharmaceuticals and Peninsula Pharmaceuticals and had positions of increasing responsibility at Genentech. She has over 30 years of experience in managing regulatory affairs, compliance and quality assurance. Ursula earned degrees from University of Nebraska and Creighton University.​

Paola Grandi, Ph.D.

Chief Scientific Officer

Paola is widely regarded as a scientific leader in the field of immuno-oncology and is responsible for directing the clinical and translational research program at Cold Genesys. Paola earned a Ph.D. in Biochemistry from the University of Ferrara (Italy) in 2001 before moving to the U.S. to pursue her interests in oncolytic Herpes Simplex Virus-based vectors for the treatment of recurrent malignant glioblastoma. After four years of post-doctoral research at the Massachusetts General Hospital in Boston, Paola joined the Departments of Neurological Surgery and Microbiology and Molecular Genetics at the University of Pittsburgh School of Medicine where she developed the next-generation Oncolytic HSV-based vectors armed with novel payload combinations that altered the tumor microenvironment (TME) to promote the development of anti-tumor immunity. As an NIH funded principal investigator, she carried out pioneering work to combine the use of retargeted HSV vectors with cellular microRNA regulation of viral genes in non-tumor tissue to limit vector oncolytic activity to brain tumors. Her academic research produced several key patents that provided the core technologies to establish a start-up oncolytic vector company, Oncorus, Inc. in Cambridge, MA as company co-founder, scientific advisory board member and early stage director of company research.​

Georg Roth, Ph.D.

Chief Technical Officer

Georg currently serves as Chief Technology Officer and is responsible for technical operations at CG Oncology. He has over 30 years of experience in the biopharmaceutical industry, developing biological processes and directing manufacturing operations. Until 2019, Georg was COO and SVP Technical Operations at Sillajen Biotherapeutics where he oversaw U.S. operations and headed all technical functions for the development of oncolytic viruses. Prior to Sillajen Biotherapeutics, Georg was VP Technical Operations at Jennerex. Earlier in his career, he held roles of increasing responsibility at Dynavax Technologies, Berlex Biosciences and Schering AG.​

Bing Kung

Vice President, Business Development

Bing has over 15 years of life science industry experience as a business development executive, investment banker and scientist. He has been involved in over 75 partnership, M&A and financing transactions in the life science sector, including those for immuno-oncology and platform technology companies. Most recently, Bing managed business development activities at Ascendancy Healthcare, which provided Western-based companies partnership solutions enabling entry and commercialization of their biopharmaceutical products into China and other high-growth Asian markets. Previously, he served as Vice President at Torreya Partners, a boutique life science investment bank, and also worked at MTS Health Partners and Aquilo Partners. Bing began his career as a research scientist in the Divisions of Oncology and Neurology at The Children's Hospital of Philadelphia, where he authored a number of peer-reviewed publications on the molecular basis of the pediatric solid tumor neuroblastoma. He received his Master's in Biotechnology and his Bachelor’s in Biology from the University of Pennsylvania.

John McAdory

Vice President, Clinical Operations

John has spent 20 years in global clinical research specializing in the development novel oncolytic therapies. He has led global clinical operations from clinical study design to submission of final study report including BLA filing. John’s expertise in strategy development, risk management, project planning and execution has consistently led to achieving program goals. With a Six Sigma Green Belt, John specializes in identifying key areas to find efficiency in clinical study conduct to save time and reduce cost. John previously held management positions with increasing roles and responsibilities at SillaJen, Inc, Janssen, Inc, and Amgen. John is a graduate of Hampton University with an BS in Biology and has a Masters in Health Administration from the University of North Carolina, Chapel Hill.

Jeffrey Ouano

Vice President, Quality Assurance

Jeff has more than 25 years of quality experience in drug development that spans across small molecules, biopharmaceuticals, oncolytic viruses and medical devices. Jeff most recently served as the global Head of Quality at SillaJen Biotherapeutics responsible for all aspects of GxP quality oversight from drug development through commercialization. He has had positions of increasing responsibility at Exelixis and has held quality positions at PDL, Xoma, Aviron, Chiron and Abbott Laboratories. Jeff graduated from San Jose State University with a Bachelor of Science degree in Molecular Biology and Chemistry.

Amy Steele

Vice President, Controller

Amy joined CG Oncology as Vice President, Controller in July 2016 and is responsible for CG Oncology’s global finance and accounting activities. Prior to joining CG Oncology, she served as the Associate Director, Finance & Business Operations at TWi Pharmaceuticals USA, Inc. and Genovi Pharmaceuticals, Inc. and was responsible for setting up of multiple corporate entities in the US, UK and Taiwan, implementing global ERP system, obtaining state wholesale and virtual manufacturing licenses for generic products as well as transfer pricing analysis. Amy brings many years of experience in financing, accounting and internal audit and received her B.A. degree in Business Economics / Accounting from University of California Los Angeles.

Board of Directors

Arthur Kuan

Chief Executive Officer

Arthur currently serves as Chief Executive Officer and Director on the Board at CG Oncology, a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies, including an oncolytic virus for the treatment of bladder cancer and a variety of other solid tumor types. Arthur is a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, and plays an active role in managing the fund’s portfolio companies. Previously, Arthur was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. He began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Arthur received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.

Ronald Cheng

Managing Director, Wellchamp Capital

Ronald has more than 20 years of experience in the Finance and Investment realm with an emphasis in media and biotechnology. He is the Founder and Managing Director at Wellchamp Capital Limited, a Hong Kong SFC registered asset management and investment advisory firm. In 2002, Ronald was Investor and Director of Plasmagene Bioscience, a biotechnology company founded by Dr. Alex Yeung, which eventually became listed as a part of the Hong Kong Stock Exchange (SEHK). Ronald was also Investor and Director of New Media Corp, a telecommunications media company invested in news and publication since 1975. Ronald holds a B.S. from The Chinese University of Hong Kong in Business Administration.

Jim Mulé, Ph.D.

Director of Cell-based Therapies, Moffitt Cancer Center

Jim is Associate Center Director, the U.S. Senator Connie Mack (ret.) & Family Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida. He is recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in melanoma. His translational work in this area has helped to develop new treatments for advanced cancer patients. He has published nearly 200 articles. Jim serves on Advisory Boards of numerous biotechnology and pharma companies as well as investment funds (e.g., OncoPep, Fulgent Diagnostics, UbiVac, Lion Biotech, Orpheus Therapeutics, Vault Pharma, Celgene, Select BioVenture Partners, Noble Life Science Partners, among others). Jim remains a long-standing special government employee to the FDA (CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A). Jim also serves on the Editorial Boards of several peer-reviewed journals, including Scientific Reports (nature.com), Journal of Immunotherapy, and Cancer Immunology Research (AACR). Jim received his professional degrees from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. He then received his formal postgraduate training at the Surgery Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, where he became a Senior Investigator with tenure. Jim moved to Palo Alto, CA, where he helped to launch and scientifically direct two biotechnology companies and was also an adjunct professor at Stanford University. He then moved to Ann Arbor, Michigan to become the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Comprehensive Cancer Center, the Maude T. Lane Endowed Professor of Surgery with tenure, Department of Surgery, and Professor in the Department of Internal Medicine.

Leonard Post, Ph.D.

Chief Scientific Officer, Vivace Therapeutics

Len has over three decades of pharmaceutical R&D experience. He is currently Chief Scientific Officer at Vivace Therapeutics. Previous experience included roles as Chief Scientific Officer of BioMarin, Chief Scientific Officer of LEAD Therapeutics, SVP of R&D at Onyx Pharmaceuticals, and positions at Parke-Davis and Upjohn. His experience with oncolytic viruses began with the adenovirus program at Onyx, and later as a member of the Boards of Directors of BioVex and then Viralytics. He is currently a member of the boards of directors at Vivace, Orphagen, Fedora, and Oxyrane. Len has a Ph.D. in Biochemistry and did postdoctoral work in virology, including some of the early work on genetic engineering of herpes simplex virus.

Jue Pu

Lepu Medical

Jue leads the cancer biomarker and liquid biopsy research and development at Lepu Medical. She also leads international investment for Lepu Medical, with successful investments including Viralytics (acquired by Merck). Jue holds a Master of Science degree in Materials Science Engineering at Stanford University. She holds a dual undergraduate degree, summa cum laude, from the Wharton School of Finance and Materials Science Engineering at the University of Pennsylvania.

Simone Song

Senior Partner, ORI Capital

Simone is Founder and Senior Partner of ORI Capital. She was the former Head of Goldman Sachs Healthcare Investment Banking for Greater China. Simone has more than 25 years of experience in healthcare sector. Prior to joining Goldman Sachs, she was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers, and an executive board advisor to AXA Asia Pacific Holdings. Simone holds a B.A. in Economics from Fudan University in China and an M.A. in Economics from Claremont Graduate School in the United States.

Contact

CG Oncology, Inc.

400 Spectrum Center Drive
​Suite #2040
​Irvine, CA 92618